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Increased Risk for Substance Use-Related Problems in Autism 
Spectrum Disorders: A Population-Based Cohort Study
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risk of substance use-related problems. The risk of substance 
use-related problems was the highest among individuals with 
ASD and ADHD. Further, risks of substance use-related 
problems were increased among full siblings of ASD pro-
bands, half-siblings and parents. We conclude that ASD is a 
risk factor for substance use-related problems. The elevated 
risks among relatives of probands with ASD suggest shared 
familial (genetic and/or shared environmental) liability.
Keywords Autism spectrum disorder · Addiction · 
ADHD  · Intellectual disability · ICD
Introduction
Substance use-related problems have traditionally been 
considered rare in autism spectrum disorders (ASD), since 
the core features appeared to reduce the risk of using psy-
choactive substance. (Ramos et al. 2013; Santosh and Mijo-
vic 2006) Yet, substance use-related problems have been 
observed among 19–30 % patients with ASD, at least in 
clinical settings (Hofvander et al. 2009; Sizoo et al. 2010). 
It has been suggested that the high rates of substance use-
related problems may be attributed to comorbidity between 
ASD and attention deficit hyperactivity disorder (ADHD) 
(Palmqvist et al. 2014). Indeed, both ADHD and intellectual 
disability frequently co-occur with ASD (Hofvander et al. 
2009; Buck et al. 2014) and are linked to substance use-
related problems (Carroll Chapman and Wu 2012; Lee et al. 
2011; Chang et al. 2014). Since psychiatric disorder comor-
bidity is mor  likely to be noted in highly selected clinical 
populations, the setting might considerably influence rates 
of concurrent, documented substance use-related problems 
(Hofvander t al. 2009; Jensen and Steinhausen 2014; Buck 
et al. 2014). One epidemiological (Abdallah et al. 2011) 
Abstract Despite limited and amb guous empirical data, 
substance use-related problems have been assumed to be 
rare among patients with autism spectrum disorders (ASD). 
Using Swedish population-based registers we identified 
26,986 individuals diagnosed with ASD during 1973–2009, 
and their 96,557 non-ASD relative . ASD, without diag-
nosed comorbidity of attention deficit hyperactivity disorder 
(ADHD) or intellectual disability, w s related to a doubled 
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code F84). A prior validation study found that 96 % of reg-
ister-based ASD diagnoses were consistent with ASD when 
medical journals were scrutinized (Idring et al. 2012).
Relatives
We used linkage through the Multi-Generation Register to iden-
tify substance use-related problems among unaffected (with-
out an ASD diagnosis) full siblings (N = 30,456), half-siblings 
(N = 15,946), and parents (N = 50,155) of probands with ASD.
Outcome
Substance use-related problems were defined as one or more 
of: substance use disorder, any conviction for a substance-
related crime, substance-related death (EMCDDA 2009), and 
alcohol-related somatic disease as defined in ICD (Table S1).
Covariates
Co-morbidity
Analyses were stratified on probands’ psychiatric comorbid-
ity with ADHD (ICD-9 code 314; ICD-10 codes F90.0, F90.1, 
F90.8 and F90.9) and/or ID (ICD-8 codes 310 to 315; ICD-9 
codes 317–319; ICD-10 code F70-F93 and F79). Diagnostic 
data were extracted from the National Patient, Pastill, and 
Habilitation Registers. Pharmacotherapy (dispensed pre-
scriptions) with stimulant (ATC codes N06BA01, N06BA02 
or N06BA04) or non-stimulant (ATC code N06BA09) 
ADHD medications from the Swedish Prescribed Drug Reg-
ister was also used to identify ADHD (Skoglund et al. 2014).
Socio-Demographic Covariates
Data on income and education were extracted from the Edu-
cation Register, the LISA database and/or Censuses from 
1970, 1975, 1980, 1985 and 1990. As an indicator of family 
economic status, we used disposable family income within 
the first 15 years of life, presented as population income per-
centile for the respective time period. The highest level of 
education obtained by either parent was used and the Migra-
tion Register provided data on parental country of birth. Miss-
ing data were not replaced but categorized as “unknown”.
Statistical Analyses
Association Between Autism Spectrum Disorder  
and Substance Use-Related Problems
Similar to previous studies (Butwicka et al. 2014; Sullivan 
et al. 2012; Kyaga et al. 2011; Larsson et al. 2013) we used 
a matched cohort design to estimate the risk of substance 
study found a similar risk of an alcohol abuse reg ster-based 
diagnosis among 414 ASD indiv duals from the Da i h 
Historic Birth Cohort compar  to non-ASD controls. In 
contrast, recent data from two large, population-based twin 
cohorts suggested that autistic-like traits do increase the risk 
of substance use disorder (Lundstrom et al. 2011; De Alwis 
et al. 2014), implying that similar a sociations can be pres-
ent in less selected samples of individuals with ASD.
We aimed to investigate the risk of substance use-related 
problems in ASD. We also tested if any association between 
ASD and substance use-related problems could be related to 
comorbidity with ADHD or intelle tual disability (ID). To 
elucidate if shared familial factors underlie both ASD and 
substance use-related problems, w  xamin  the pattern of 
substance use-related problems al o among unaffect d rela-
tives of individuals with ASD.
Methods
Registers
We linked Swedish longitudina , populati -based registers: 
the National Patient Register, wh c contains all inpatient
medical care (1973-) and outpatient, non-GP, specialist care 
(2001-), the Clinical Database for Child and Adolescent Psy-
chiatry in the Stockholm County (Pastill) (Lundh et al. 2013), 
the Habilitation Register (Idring et al. 2012), the Swed sh 
Prescribed Drug Register (2005-) (Wettermark et al. 2007), 
the Cause of Death Register (National Board of Health and 
Welfare 2009), the National Crime Register (National C un-
cil for Crime Prevention 2013), the Swedish Register of 
Education (Statistics Sweden 2011a), the Natio al Censuses 
from 1960 to 1990 (Statistics Sweden 1992), he Integrated 
Database for Labor and Market Research (Statistics Sweden 
2011b), the Total Population Register and th Multi-Genera-
tion Register (Ekbom 2011). Unique personal identification 
numbers, assigned to each Swedish resident, enabled data 
linkage across registers. National Swedish administrative 
medical registers contain sys emat cally and longitudinally 
collected information due to mandatory reporting. Excellent 
diagnostic validity has be n reported for many disorders; 
consequently, these registers have pr viously been used in 
many epidemiological investi ations.
Subjects
We identified 26,986 probands with an autism spectrum 
disorders (ASD) among all individuals born in Swed n
between January 1, 1973 and December 31, 2009. ASD 
diagnoses from the National Patient, Pastill, or Habi itation 
Registers were defined according to WHO’s International 
Classification of Disease (ICD) (ICD-9 code 299; ICD-10 
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Results
We identified 26,986 probands with an ASD diagnosis and 
compared them with 1,349,300 non-ASD individuals matched 
on sex, birth year and county of birth. The median age at 
the time of first ASD diagnosis was 13.8 years [interquar-
tile range (IQR) = 8.8–18.4]. While 3.4 % (N = 91 ) of ASD 
patients had a preexisting substance use disorder diagnosis 
when diagnosed with ASD only 0.8 % (N = 10,789) of con-
trols had a substance use disorder diagnosis when included in 
the study (p < 0.001). Descriptive variables differed slightly 
between groups with the most marked differences for paren-
tal age, education and family income (Table S2).
Autism Spectrum Disorders and Risk of Substance  
Use-Related Problems
Probands had a substantially increased risk of any sub-
stance-related problem (OR 3.3; 95 % CI 3.1–3.6), such as 
substance use disorder (OR 5.2; 95 % CI 4.9–5.6), somatic 
disease linked to alcohol misuse (OR 5.9; 95 % CI 2.7–13.0), 
substance-related crime (OR 1.4; 95 % CI 1.2–1.5) and death 
(OR 3.0; 95 % CI 1.3–6.9). Within the substance use disorder 
category, the highest risk was found for drug use disorder 
(OR 8.5; 95 % CI 7.7–9.3), followed by tobacco (OR 6.4; 
95 % CI 3.8–10.5) and alcohol use disorder (OR 4.0, 95 % CI 
3.7–4.4). Adjustment for parental age, region of birth, educa-
tion and family income did not change the results (Table 1).
All risk estimates were elevated among ASD probands diag-
nosed with ICD-10 criteria, whereas probands diagnosed 
with earlier ICD versions, appeared less likely to develop 
substance-related problem compared to non-ASD individu-
als (OR 0.4; 95 % CI 0.2–0.6) (Table S3).
Subsequently, we stratified analyses by ASD comorbid-
ity with ADHD and/or ID (Table 2). Although ASD pro-
bands without such comorbidity also had increased risk of 
substance use-related problems (OR 2.6; 95 % CI 2.4–2.9), 
comorbid ADHD (OR 8.3; 95 % CI 7.4–9.2) or ADHD with 
ID (OR 4.6; 95 % CI 3.7–5.8) entailed a substantially higher 
risk, especially for substance use disorder. ASD comorbid 
with ID alone was not associated with an increased risk of 
any substance use-related problems (OR 1.1; 95 % CI 0.9–
1.3), when all outcomes where regarded as one group.
When the risk was calculated separately for specific out-
comes, the risk of substance use disorder was increased (OR 
1.8; 95 % CI 1.4–2.2), but the risk of being convicted of 
a substance-related crime was decreased (OR 0.2; 95 % CI
0.1–0.4). Odds ratios adjusted for parental education, family 
income and substance use disorder prior to ASD diagnosis 
showed a similar pattern (Table 2).
use-related problems in two tudy population: probands 
with ASD and their relatives. Probands with ASD were 
matched on sex, birth year and county of birth to gen-
eral population controls drawn from the To al Population 
Register. The number of controls for each ASD proband 
was restricted to 50 individuals ran omly selected from 
the data set with matched individuals  Odds ratios (ORs) 
for each ASD proband were estimated from condit onal 
logistic regression models stratified on matched sets to 
account for the matching by sex, birth year and county f 
birth. In analysis on relatives, f ll sibling, half-sibling and 
parents of probands with ASD wer  compared to ma ched 
relatives of non-ASD individu s, to full s bling controls, 
half-sibling controls, and parent controls, respectively. 
Multivariate analyses were adjusted for family income,
parental education and country of origin. g neralized esti-
mating equations (GEEs) was used to correct for familial 
clustering of data.
When only familial confoundi g is conside ed, results 
from this method will be compar bl to tho e from ordi-
nary within-sibling analyses. In add tion, we could adjust 
for non-familial confounding by using simple matching to 
population control (birth cohort effects, diag ostic patters 
different for gender and counties) with equal ime at risk 
between the compared groups (bias due to le t truncation or 
right censoring). (Lundstrom et al. 2014).
All statistical analyses were cond c ed with SAS sof-
ware (version 9.3; Cary, NC, USA).
Sensitivity Analyses
First, we investigated the risk of subst nce-related prob-
lems among ASD probands in comparison to their popu-
lation controls, separately for patients diagnosed with 
ASD on ICD-10 criteria and those diagnosed with ICD-8 
or ICD-9. Second, to test whether there was any secular 
trend, we compared risks among ASD individuals born 
1990–2009 with those born 1973–1989. Thir , we investi-
gated the effect of the timing of ADHD and/or ID d agno-
ses on risk of substance-related problems. Hence, the risk 
of substance-related problems was estim ted separately 
for ASD probands who received all final neuropsychiatric 
diagnoses before substance use disorder was diagnos d. 
Analyses were undertaken separately for ASD pr bands 
without neuropsychiatric orbidity, and with ADHD 
and/or ID.
The study was approved by the research thics om it-
tee at Karolinska Institutet, Stockholm, Sweden Protocol 
nr 2009/5:10. No individual consent was needed since data 
were strictly register-based.
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Autism Spectrum Disorder and Substance Use-Related 
Problems
Up to now, many clinicians have assumed that substance 
use-related problems are rare among patients with ASD and, 
if present, primarily due to comorbid ADHD (Palmqvist et 
al. 2014). This notion has also been supported by clinical 
studies. A retrospective chart review of 97 youths with ASD 
found lower rates of substance use compared to psychiatri-
cally treated controls (3.1 vs. 16.7 %); he three boys with 
ASD and substance use also had comorbid ADHD (San-
tosh and Mijovic 2006). Similarly, when 70 adults with 
ASD were compared to 70 subjects with ADHD, substance 
use rates were lower among those with ASD than ADHD 
patients (30 vs. 58 %). (Sizoo et al. 2010) However, both 
ADHD (Groenman et al. 2013) nd psychiatrically treated 
patients (Mangerud et al. 2014) are a increased risk of sub-
stance use-related problems, which makes them less suit-
able as control subjects. To our knowledge, although prior 
research argued that substance use-related problems are not 
an issue among ASD individuals (Ramos et al. 2013), no 
prior clinical study with ASD patients has compared them 
to non-ASD population controls. However, more recent 
twin studies provide a different perspective. Lundström et 
al. were the first to report that autistic-like traits actually 
increase the risk of substance abuse (OR 7.4; 95 % CI 3.5–
15.7) (Lundstrom et al. 2011), findings which were recently 
confirmed in Australia (De Alwis et al. 2014). These twin 
studies focused on autistic-like traits as a behavior pattern 
within the normal spectrum of social interest and compe-
tence and similar to that found in ASD, but without investi-
gating the formal diagnostic criteria for persistence, distress 
or functional impairment required for a diagnosis. Thus, 
these studies did not address whether an ASD diagnosis was 
related to substance use-related problems.
In a sensitivity analysis, the risk for sub tance-related 
problems was estimated sepa ately for ASD probands who 
received all neuropsychiatric diagnoses before a subs an e use 
disorder diagnosis. This suggested that odds ratios were simi-
larly increased in ASD proband  with (OR 1.9; 95 % CI 1.6–
2.3) and without comorbid ADHD (OR 1.6; 95 % CI 1.4–1.8), 
while those with comorbid ID appeared to have a decreased 
risk (OR 0.6; 95 % CI 0.5–0.8). The largest difference in sub-
stance use-related problems across comorbidity groups was 
seen for substance-related rime, which was mo  likely only 
among ASD probands with ADHD (OR 1.7; 95 % CI 1.3–2.3).
In contrast, ASD probands without ADHD (OR .7; 95 % CI 
0.5–0.8) were actually less likely to commit substance related 
crime than were population cont ols (Tabl S4).
Relatives’ Risk of Substance Use-Related Problems
Compared to their matched con rols, all ives of probands had 
weakly but significantly increased risk for any substance-related 
problem (Table 3 ). Full siblings and parents were at weakly to 
moderately increased risk for all substance use-related prob-
lems, including substance-related death. Half-siblings exhibited 
significantly increased risk for substance-related crime and sub-
stance use disorder. The increased risk of substance use- lated 
problems among relatives was present regardless of probands’ 
comorbidity. Finally, adjustment for socio-demographic covari-
ates did not change results materially (data not shown).
Discussion
We found that ASD was associated with increase  risk for 
a range of substance use-related problems, and the family 
data suggested that this was du to share  liab lity bet e n 
ASD and substance use-related problems between r lativ s.
Substance-related 
problem
Probands Unexposed individualsU ivariate 
analysis
Multivariate 
analysisa
Patients with ASD 
N = 26,986 n (%)
Non-ASD individuals 
N = 1,349,300 n (%)
Crude OR (95 % 
CI)
Adjusted OR 
(95 % CI)
Any problem 1079 (4.0) 17,643 (1.3) 3.3 (3.1–3.6)***2.6 (2.4–2.7)***
Substance use disorder980 (3.6) 10,228 (0.8) 5.2 (4.9–5.6)***3.9 (3.6–4.2)***
Alcohol 574 (2.1) 7519 (0.6) 4.0 (3.7–4.4)***3.1 (2.8–3.4)***
Drugs 579 (2.1) 3638 (0.3) 8.5 (7.7–9.3)***5.6 (5.1–6.2)***
Tobacco 17 (0.1) 134 (0.0) 6.4 
(3.8–10.5)***
4.6 (2.8–7.8)***
Crime 259 (1.0) 9687 (0.7) 1.4 (1.2–1.5)***1.1 (1.0-1.2)
Somatic disease7 (0.0) 59 (0.0) 5.9 
(2.7–13.0)***
4.3 (1.9–9.7)***
Death 6 (0.0) 99 (0.0) 3.0 (1.3–6.9)**2.0 (0.9–4.6)
***p value <0.001
aAdjustment for parental education, family income and substance use disorder prior to ASD diagnosis
Table 1 Rates and odds ratios 
(with 95 % confidence interval) 
for substance use-related 
problems in autism spectrum 
disorder (ASD) probands and 
matched non-ASD population 
controls
J Autism Dev Disord (2017) 47:80–89 83
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over time. In fact, substantial time trends in substance use 
have been described for the general population (Kraus et 
al. 2015b, a). A cohort effect is one of several factors that 
may explain such temporal changes in substance use-related 
problems. The broadening of diagnostic criteria has previ-
ously been blamed for increase in ASD prevalence (Lund-
strom et al. 2015). Hence, while ASD patients diagnosed 
after 1996 with ICD-10 appeared to have increased risk of 
substance use-related problems relative to control subjects, 
prior more narrow diagnostic practice may have excluded 
ASD patients with substance use-related issues or assigned 
other diagnoses to them. Thus, the remaining, narrowly 
defined ASD patient group will be perceived as being “pro-
tected” from substance use-related problems.
Increased risk of substance use-related problem  seems 
to contradict global negative attitudes towards psychoac-
tive substances observed among ASD patien s (Ramos et
al. 2013). Individuals with ASD may find them helpful to 
reduce tension and enhance s cial skills mor  often than 
non-ASD controls do (Cludius et a .2013).
Cohort Effect and Comorbidity
So, why have the idea that ASD patients e somehow 
protected from substance use-related problems been q ite 
persistent? One possibility is that sub tance use-related 
problems in individuals with ASD were indeed le s com-
mon in the past, but that some facto (s) cau ed an increase 
Table 3 Rates and odds ratios (with 95 % confidence interval) for substance use-related problems in relatives of probands with autism spectrum 
disorders (ASD) compared to relatives of matched non-ASD controls
RelativeSubstance-related 
problem
Rat  n (%)Total Comorbidity in probands
None ADHD ID ADHD  + ID
Crude OR  
(95 % CI)
Crude OR  
(95 % CI)
Crude OR  
(95 % CI)
Crude OR  
(95 % CI)
Crude OR  
(95 % CI)
Full siblings 
N = 30,456
Any problem1191 (3.9)1.5 (1.4–1.6)***1.3 (1.2–1.5)***1.8 (1.5-2.0)***1.3 (1.1–1.5)**1.9 (1.6–2.4)***
Substance use 
disorder
831 (2.7)1.6 (1.5–1.7)***1.4 (1.2–1.6)***2.0 (1.8–2.3)***1.3 (1.1–1.6)***2.1 (1.7–2.7)***
Alcohol 605 (2.0)1.5 (1.4–1.6)***1.3 (1.1–1.5)***1.9 (1.6–2.2)***1.3 (1.0-1.5)*2.1 (1.6–2.7)***
Drugs 327 (1.1)1.9 (1.7–2.1)***.7 (1.5–2.1)***2.6 (2.1–3.2)***1.4 (1.1–1.9)*2.4 (1.6–3.4)***
Tobacco 13 (0.0)2.1 (1.1-4.0)*2.0 (0.9–4.6)2.0 (0.6–6.4)3.1 (0.8–12.9)–a
Crime 530 (1.7)1.3 (1.2–1.4)***1.2 (1.0-1.4)*1.5 (1.3–1.8)***1.3 (1.0-1.6)*1.6 (1.1–2.2)**
Death 10 (0.0)3.0 (1.3–6.7)**1.9 (0.6–6.2)7.4 (2.5–21.3)***1.9 (0.4–7.7)6.3 (0.8–51.4)
Somatic disease4 (0.0)1.5 (0.6–4.2)1.3 (0.3–5.4)2.0 (0.3–15.2).3 (0.3–17.2)–a
Half siblings 
N = 15,946
Any problem1264 (7.9)1.2 (1.1–1.3)***1.2 (1.1–1.3)**1.3 (1.2–1.5)***1.1 (0.9–1.2)1.3 (1.1–1.6)**
Substance use 
disorder
848 (5.3)1.3 (1.2–1.4)***1.2 (1.1–1.4)**1.4 (1.2–1.6)***1.2 (1.0-1.4)1.5 (1.2–1.9)***
Alcohol 589 (3.7)1.2 (1.1–1.4)***1.2 (1.0-1.4)*1.3 (1.1–1.5)**1.3 (1.0-1.6)*1.2 (0.9–1.6)
Drugs 401 (2.5)1.4 (1.2–1.5)***1.2 (1.0-1.4)*1.5 (1.3–1.9)***1.2 (0.9–1.5)2.0 (1.5–2.7)***
Tobacco 6 (0.0)0.8 (0.3–1.7)0.3 (0.0-1.9)1.4 (0.4–4.6)–a 2.2 (0.5–9.4)
Crime 706 (4.4)1.2 (1.1–1.3)***1.2 (1.0-1.4)**1.3 (1.1–1.5)***1.0 (0.8–1.2)1.1 (0.8–1.4)
Death 12 (0.1)1.4 (0.7–2.6)1.5 (0.6–3.6)1.7 (0.6–4.7)–a 3.0 (0.9–9.4)
Somatic disease5 (0.0)2.3 (0.9–5.9)1.9 (0.4–8.3)4.2 (0.9–19.2)–a 3.8 (0.5–31.5)
Parents 
N = 50,155
Any problem5720 (11.4)1.5 (1.4–1.5)***1.3 (1.2–1.3)***2.0 (1.9–2.1)***1.2 (1.1–1.3)***1.7 (1.5–1.8)***
Substance use 
disorder
3110 (6.2)1.7 (1.6–1.8)***1.4 (1.3–1.5)***2.3 (2.2–2.5)***1.4 (1.3–1.6)***2.1 (1.9–2.4)***
Alcohol 2401 (4.8)1.7 (1.6–1.7)***1.4 (1.3–1.5)***2.2 (2.0-2.4)***1.4 (1.3–1.6)***2.2 (1.9–2.5)***
Drugs 1187 (2.4)1.9 (1.8-2.0)***1.5 (1.3–1.6)***2.9 (2.6–3.2)***1.5 (1.3–1.7)***2.2 (1.8–2.7)***
Tobacco 137 (0.3)1.5 (1.3–1.8)***1.6 (1.2-2.0)***2.0 (1.5–2.7)***0.6 (0.3-1.0)2.4 (1.4–4.1)**
Crime 3855 (7.7)1.3 (1.3–1.4)***1.1 (1.1–1.2)***1.9 (1.8-2.0)***1.1 (1.0-1.2)1.5 (1.3–1.6)***
Death 161 (0.3)1.8 (1.5–2.1)***1.5 (1.2–1.9)**2.7 (2.1–3.5)***1.2 (0.8–1.8)2.2 (1.2-4.0)**
Somatic diseases201 (0.4)1.5 (1.3–1.8)***1.3 (1.0-1.6)*2.0 (1.5–2.6)***1.7 (1.2–2.2)***1.3 (0.8–2.3)
Results stratified by comorbidity in probands
ADHD attention deficit hyperactivity disorder, ID intellectual disability
*p value <0.05;**p value <0.01; ***p value <0.001
aOR and 95 % CI were not calculable due to no observations
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shared genetic or environmental factors, or epigenetic 
mechanisms. First, ASD and substance use-related prob-
lems may share genetic risk variants (Zuo et al. 2013). Sec-
ond, parental substance use disorder may also increase de 
novo mutation rates, found to be involved in ASD (Sand-
ers et al. 2012). Exposure to psychoactive substances may 
be related to epigenetic modifications in germ cells (Govo-
rko et al. 2012) and lead to high risk of ASD in offspring. 
Third, associations between ASD and substance use-related 
problems may be due to shared environmental factors. For 
example, exposure to alcohol during pregnancy may lead to 
fetal alcohol spectrum disorder and autistic-like symptoms 
within the course of this condition (Stevens et al. 2013). In 
addition, severely neglected children of parents addicted to 
psychoactive substance may present symptoms of reactive 
attachment disorder which, particularly when accompanied 
with autistic-like symptoms, may increase the probability of 
receiving an ASD diagnosis (McCullough et al. 2013).
Interestingly, full siblings and parents of ASD probands 
also had substantially increased risks of substance-related 
death. This association among parents may be explained 
by older age at the time of study (median age 47.1 years; 
IQR 41.4–53.9) enabling sufficient number of outcomes to 
occur. However, siblings were not older than probands at the 
time of inclusion (median age 16.9 years; IQR 10.8–22.7). 
We can only speculate that the same familial factors may 
be causal in substance use-related problems among ASD 
probands may lead also to higher risks of substance-related 
death among their non-ASD relatives. For example, as pre-
viously mentioned, a rigid norm-abiding interpersonal style 
characteristic for ASD may protect from life-threatening 
activities under the influence of a psychoactive substance.
Study Strengths and Limitations
Strengths include the large scale population-based design, 
prospectively collected data from nationwide registries, 
stratification by comorbid disorders, statistical control for 
socio-demographic confounders, and analysis of familial 
aggregation data from relatives. Nevertheless, some limita-
tions deserve comments.
First, information bias should be considered. For exam-
ple, substance use-related problems may be more likely 
to be detected among individuals with ASD who do have 
regular contact with habilitation and mental health services. 
However, similar results were also obtained from other 
resources; significantly increased risk for substance-related 
crime from the National Convictions Register and for alco-
hol-related somatic disease, diagnosed by other medical 
specialists. An information bias may also act in an opposite 
direction. Individuals with ASD had not statistically signifi-
cant, but slightly higher prevalence of substance use disor-
der prior to ASD diagnosis then healthy controls.
The risk of substance use-related problems may still dif-
fer across patient subgroups depending on ADHD and ID 
comorbidity. For example, increased rates of substance use-
related problems in ASD have been ttributed to comorbid 
ADHD (Palmqvist et al. 2014). S ntosh et al. arg ed that 
comorbid ID may protect ASD patients from bstance use-
related problems (Santosh and Mijovi  2006). This was 
supported by studies suggesting th t substance use-related 
problems were increased among patients w th ASD, but 
without intellectual disability co orbidities (Hofvan er 
et al. 2009; Sizoo et al. 2010).In this study, the increased 
risk of substance use-relat d problems suggested among 
ASD patients was unlikely to result entirely from comor-
bid conditions, since probands d agnosed solely with ASD 
had an almost doubled risk of substance use-related prob-
lems compared to non-ASD controls. However, comor-
bid ADHD and ID seemed to modify the overall risk. For 
example, co-occurring ADHD was associated with further 
increased risk of substance use-related problems, whereas 
ID was associated with a lowered risk. It is possible that 
the highly increased risk among patient  w th comorbid
ADHD is due to diagnostic bias re ated to interpretati n of 
ICD by clinicians. Taken literally, ICD-10 do s not allow a 
comorbid ADHD diagnosis in the presenc  of several other 
diagnoses; ASD, anxiety-, and mood disorders. Si ult-
neous diagnoses of ASD and ID is ll wed, provided that 
autistic-like symptoms cannot be explained by ID. Thus, 
clinicians may be reluctant t  ssign ASD and ID diagn ses 
to patients already diagnosed with ASD. In contrast, among 
patients with ASD and later substance use disorder, clini-
cians may be more likely to exchange ASD with an ADHD 
diagnosis. To test this poss bility, we perf rmed sensitivity 
analyses with those ASD patients who assigned with ASD, 
ADHD and ID before a substance use disorder diagnosis. 
As a result, it turned out that patients with ASD only and 
ASD with ADHD are actually on comparable risks of sub-
stance use-related problems (OR 1.6 vs. 1.9) and previously 
described extremely high risk in patents wi h ASD and 
ADHD seems to be due diagnostic bias s.
Common Familial Etiology
To further investigate a possible shared familia  backg und 
to the association between ASD and subs ance use-relate  
problems, we analyzed the risk among on-ASD relatives 
of ASD probands. Consistent with prior reports of high rat s 
of alcohol abuse among relative  of ASD p t ents (Mi s et 
al. 2003) and higher risk of ASD among offspring of par-
ents with alcohol abuse (Sundquist et al. 2014), our results 
suggested increased risk of substance use-related prob-
lems among 1st degree relat ves and half-sibl ng  without 
an ASD diagnosis. This supports a shared familial liability 
which may in turn reflect one or more possible explanations; 
J Autism Dev Disord (2017) 47:80–8986
123
Acknowledgments This study was completed thanks to a Swedish 
Institute (SI) scholarship within the SI Baltic Sea Region Cooperation/
Visby Programme No. 00286/2013 (AB). The project was supported 
by grants from the Swedish Research Council, through the Swedish 
Initiative for Research on Microdata in the Social and Medical Sci-
ences (SIMSAM) framework Grant No. 340-2013-5867 and the Swed-
ish Research Council for Health, Working Life and Welfare. We are 
grateful for the skilled technical assistance of Marcus Boman from 
Department of Medical Epidemiology and Biostatistics, Karolinska 
Institutet.
Author Contributions AB, LF and PL designed the study.  AB 
analysed the data. AB, NL and PL wrote the first draft of the paper. 
All authors contributed to interpretation of data, critically revised the 
paper and approved the final draft submitted. AB and PL have full 
access to all the data and take responsibility for integrity of the data.
Compliance with Ethical Standards
Conflict of Interest HL has served as a speaker for Eli-Lilly and 
Shire and has received a research grant from Shire; all outside the sub-
mitted work. Authors AB, NL, SL, ES, CA, LF and PL have no con-
flicts of interest to disclose.
Ethical Approval The study was approved by the Regional Ethical 
Review Board in Stockholm Sweden (2010/1258-32/5). In accordance 
with Swedish law, individual consent was not required since data were 
strictly register-based.
Open Access This article is distributed under the terms of the Creative 
Commons Attribution 4.0 International License (ht p://creativecom-
mons.org/licenses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made.
References
Abdallah, M. W., Greaves-Lord, K., Grove, J., Norgaard-Pedersen, B., 
Hougaard, D. M., & Mortensen, E. L. (2011). Psychiatric comor-
bidities in autism spectrum disorders: Findings from a Danish 
Historic Birth Cohort. European Child and Adolescent Psychia-
try, 20(11–12), 599–601. doi:10 1007/s00787-011-0220-2.
Buck, T. R., Viskochil, J., Farley, M., Coon, H., McMahon, W. M., 
Morgan, J., et al. (2014). Psychiatric comorbidity and medication 
use in adults with autism spectrum disorder. Journal of Autism 
and Developmental Disorders. doi:10.1007/s10803-014-2170-2.
Butwicka, A., Lichtenstein, P., Landen, M., Nordenvall, A. S., Nor-
denstrom, A., Nordenskjold, A., et al. (2014). Hypospadias and 
increased risk for neurodevelopmental disorders. Journal of Child 
Psychology and Psychiatry, and Allied Disciplines. doi:10.1111/
jcpp.12290.
Carroll Chapman, S. L., & Wu, L. T. (2012). Substance abuse among 
individuals with intellectual disabilities. Research in Developmen-
tal Disabilities, 33(4), 1147–1156. doi:10.1016/j.ridd.2012.02.009.
Chang, Z., Lichtenstein, P., Halldner, L., D’Onofrio, B., Serlachius, 
E., Fazel, S., et al. (2014). Stimulant ADHD medication and risk 
for substance abuse. Journ l of Child Psychology and Psychiatry, 
and Allied Disciplines, 55(8), 878–885. doi:10.1111/jcpp.12164.
Cludius, B., Stevens, S., Bantin, T., Gerlach, A. L., & Hermann, C. 
(2013). The motive to drink due to social anxiety and its rela-
tion to hazardous alcohol use. Psycho ogy of Addictive Behaviors, 
27(3), 806–813. doi:10.1037/a0032295.
Second, we could stratify our analy i  on comorbid 
ADHD and ID only when those disorders were diagnosed, 
but it impossible to rule out that patients w t  se mingly 
“pure” ASD have undiagnosed ID, ADHD, or subthresh-
old ADHD-symptoms involving sub tance use- elated 
problems. Third, the register-based design needs con-
sideration while comparing absolu e est m te rates from 
our study to those from research using population survey 
designs. For example, our absolute figures on alcohol use 
disorder are comparable to 1.5 % rates of alco l abuse 
among men and 0.7 % among females estimated in a reg-
ister-based cohort of Swedish citizens born 1973–1984 
(Gauffin et al. 2013). Yet, they evidently differ from he 
8.9 % 12-month prevalence of alcohol use disorder found 
in a Swedish population survey of those aged 15 years and 
older (WHO 2014). In other words, reg st r-based stu-
ies are likely to underestimate the absolute p valence of
substance use disorder since users not in contact with the 
treatment system are not taken into account (EMCDDA 
2004).
Fourth, it was not possibl  to disentangle if th  shared 
familial background between ASD and substance use-
related problems were best explained by genetic or shared 
environmental factors. Finally, we did not differentiate 
between Autistic disorder, Asperger´s dis rder or Pe v-
sive developmental disorder not otherwise specified which 
might have yielded different associations. Multi-site stud-
ies, although, do question the validity of the demarcation 
between these three disorders (Lord et al. 2012) and the
DSM-5 (APA, 2013), groups them all under the one single 
category of autism spectrum disorders.
Conclusions
In summary, this large populati n-based study suggests 
that individuals with ASD have higher risk f substance 
use-related problems than population controls; most likely 
because of a shared familial liability for hese condition . An 
important implication of our findings concerns diagnostics 
and treatment strategies in ASD. Increased risk of substance-
related problems in ASD suggests attention and preventive 
measures regarding substance use disorder in this popu a-
tion. Since ASD frequently co-oc urs with ADHD and intel-
lectual disability and the t ajectories of ASD into substance 
abuse may differ depending on concomitant conditions, the 
present results also highlight the need for comprehensive 
psychiatric examinations upon deciding on treatment strate-
gies for substance use disorder. Our finding of a mediating 
role of familial risk factors suggest that attempts to prevent 
or treat substance use disorder in ASD proban s sho ld 
consider also the vulnerabilities of other first degree family 
members.
J Autism Dev Disord (2017) 47:80–89 87
123
A meta-analytic review. Cl nical Psychology Review, 31(3), 328–
341. doi:10.1016/j.cpr.2011.01.006
Lord, C., Petkova, E., Hus, V., Gan, W., Lu, F., Martin, D. M., et 
al. (2012). A multisite study of the clinical diagnosis of differ-
ent autism spectrum disorders. Archives of G neral Psychiatry, 
69(3), 306–313. doi:10.1001/archgenpsychiatry.2011.148.
Lundh, A., Forsman, M., Serlachius, E., Lichtenstein, P., & Landen, 
M. (2013). Outcomes of child psychiatric treatment. Acta Psy-
chiatrica Scandinavica, 128(1), 34–44. doi:10.1111/acps.12043.
Lundstrom, S., Chang, Z., Kerekes, N., Gumpert, C. H., Rastam, M., 
Gillberg, C., et al. (2011). Autistic-like traits and their association 
with mental health problems in two nationwide twin cohorts of 
children and adults. Psychological Medicine, 41(11), 2423–2433. 
doi:10.1017/S0033291711000377.
Lundstrom, S., Forsman, M., Larsson, H., Kerekes, N., Serlachius, 
E., Langstrom, N., et al. (2014). Childhood neurodevelopmental 
disorders and violent criminality: A sibling control study. Jour-
nal of Autism and Developmental Disorders, 44(11), 2707–2716.
doi:10.1007/s10803-013-1873-0.
Lundstrom, S., Reichenberg, A., Melke, J., Rastam, M., Kerekes, N., 
Lichtenstein, P., et al. (2015). Autism spectrum disorders and 
coexisting disorders in a nationwide Swedish twin study. Jour-
nal of Child Psychology and Psychiatry, and Allied Disciplines, 
56 (6), 702–710. doi:10.1111/jcpp.12329.
Mangerud, W. L., Bjerkeset, O., Holmen, T. L., Lydersen, S., & Indre-
davik, M. S. (2014). Smoking, alcohol consumption, and drug 
use among adolescents with psychiatric disorders compared with 
a population based sample. Journal of Adolescence, 37(7), 1189–
1199. doi:10.1016/j.adolescence.2014.08.007.
McCullough, E., Stedmon, J., & Dallos, R. (2013). Narrative responses 
as an aid to understanding the presentation of maltreated children 
who meet criteria for autistic spectrum disorder and reactive attach-
ment disorder: A case series study. Clinical Child Ps chology and 
Psychiatry, 19(3), 392–411. doi:10.1177/1359104513503353.
Miles, J. H., Takahashi, T. N., Haber, A., & Hadden, L. (2003). Autism 
families with a high incidence of alcoholism. Journal of Autism 
and Developmental Disorders, 33(4), 403–415.
National Board of Health. (2009). Causes of death 2009. Stockholm: 
National Board of Health and Welfare. Official Statistics of Swe-
den Health and Medical Care.
National Council for Crime Prevention (2013). Criminal statistics 
2012. Stockholm: National Council for Crime Prevention.
Palmqvist, M., Edman, G., & Bolte, S. (2014). Screening for substance 
use disorders in neurodevelopmental disorders: A clinical rou-
tine? European Child and Adolescent Psychiatry, 23(5), 365–368. 
doi:10.1007/s00787-013-0459-x.
Ramos, M., Boada, L., Moreno, C., Llorente, C., Romo, J., & Parel-
lada, M. (2013). Attitude and risk of substance use in adoles-
cents diagnosed with Asperger syndrome. Drug and Alcohol 
Dependence 0376-8716 (P), 133(2), 535–540. doi:10.1016/j.
drugalcdep.2013.07.022.
Sanders, S. J., Murtha, M. T., Gupta, A. R., Murdoch, J. D., Raubeson, 
M. J., Willsey, A. J., et al. (2012). De novo mutations revealed 
by whole-exome sequencing are strongly associated with autism. 
Nature, 485(7397), 237–241. doi:10.1038/nature10945.
Santosh, P. J., & Mijovic, A. (2006). Does pervasive developmental 
disorder protect children and adolescents against drug and alco-
hol use? European Child and Adolescent Psychiatry, 15(4), 183–
188. doi:10.1007/s00787-005-0517-0.
Sizoo, B., van den Brink, W., Koeter, M., Gorissen van Eenige, M., 
van Wijngaarden-Cremers, P., & van der Gaag, R. J. (2010). 
Treatment seeking adults with autism or ADHD and co-mor-
bid substance use disorder: Prevalence, risk factors and func-
tional disability. Drug and Alcohol Dependence, 107(1), 44–50. 
doi:10.1016/j.drugalcdep.2009.09.003.
De Alwis, D., Agrawal, A., Reiersen, A. M., Constantino, J. N., H n-
ders, A., Martin, N. G., et al. (2014). ADHD symptoms, autistic 
traits, and substance use and misuse in adult Australian twins. 
Journal of Studies on Alcohol and Drugs, 75(2), 211–221.
Ekbom, A. (2011). The Swedish multi-g er tion regis er.Meth-
ods in Molecular Biology (Clifton N. J ), 675, 215–220. 
doi:10.1007/978-1-59745-423-0_10.
EMCDDA. (2004). EMCDDA recommended draft technical tools and 
guidelines. Key epidemiological indicator: Prevalence of prob-
lem drug use\. Li bon: European Monitoring Centre for Drugs 
and Drug Addiction.
EMCDDA (2009). Standard protocol version 3.2 for the EU Mem-
ber States to collect data and report figures for the Key indicator 
drug-related deaths. In E. p. CT.02.P1.05 (Ed.). Lisbon: European 
Monitoring Centre for Drugs and Drug Addiction.
Gauffin, K., Hemmingsson, T., & Hjern, A. (2013). The effect of 
childhood socioeconomic position n alcohol-related disorders 
later in life: A Swedish national coh rt study. Journal of Epide-
miology and Community Health, 67(11), 932–938. doi:10.1136/
jech-2013-202624.
Govorko, D., Bekdash, R. A., Zhang, C., & Sarkar, D. K. (2012). Male 
germline transmits fetal alcohol adverse effect on hypothalamic 
proopiomelanocortin gene across generat ons. Biologi al Psychi-
atry, 72(5), 378–388. doi:10.1016/j.biopsych.2012.04.006.
Groenman, A. P., Oosterlaan, J., Rommelse, N., Franke, B., Roeyers, 
H., Oades, R. D., et al. (2013). Substance use disorders in ado-
lescents with attention deficit hyperactivity disorder: A 4-year 
follow-up study. Addiction (Abingdon, Engl nd), 108(8), 1503–
1511. doi:10.1111/add.12188.
Hofvander, B., Delorme, R., Chaste, P., Nyden, A. Wen z, E., Stahl-
berg, O., et al. (2009). Psychiatric and psychosocial problems in 
adults with normal-intelligence autism spectrum disorder . BMC 
Psychiatry, 9, 35. doi:10.1186/1471-244X-9-35.
Idring, S., Rai, D., Dal, H., Dalman, C., Sturm, H., Zander, E., et 
al. (2012). Autism spectrum disorders in the Stockholm Youth 
Cohort: Design, prevalence and valid ty. PLoS One, 7(7), e41280. 
doi:10.1371/journal.pone.0041280
Jensen, C. M., & Steinhausen, H. C. (2014) Comorbid mental disor-
ders in children and adolescents with attention-deficit/hyperac-
tivity disorder in a large nationwide study. Attention Deficit and 
Hyperactivity Disorders. doi:10.1007/s12402-014-0142-1.
Kraus, L., Osthus, S., Amundsen, E. J., Piontek, D., Harkonen, J., 
Legleye, S., et al. (2015a). Changes in mortality due to major 
alcohol-related diseases in four Nor c countr es, Franc  and Ger-
many between 1980 and 2009: A comparative age-per o -cohort 
analysis. Addiction (Abingdon, Englan ), 110(9), 1443–1452. 
doi:10.1111/add.12989.
Kraus, L., Tinghog, M. E., Lindell, A., Pabst, A., Piontek, D., & Room, 
R. (2015b). Age, period and cohort effects on time trends in lco-
hol consumption in the Swedish adult population 1979 2 11. 
Alcohol and alcoholism (Oxford, Oxfordshire), 50(3), 319–327. 
doi:10.1093/alcalc/agv013.
Kyaga, S., Lichtenstein, P., Boman, M., Hultman, C., Langstrom, N., 
& Landen, M. (2011). Creativity and menta  disorder: Family 
study of 300,000 people with severe mental disorder. The Brit-
ish Journal of Psychiatry, 199(5), 373–379. doi:10.1192/bjp.
bp.110.085316.
Larsson, H., Ryden, E., Boman, M., Langstrom, N., Lichtenstein, P., 
& Landen, M. (2013). Risk of bipolar disorder and schizophrenia 
in relatives of people with attention-deficit hyperactivity disorder. 
The British Journal of Psychiatry, 203(2), 103–106. do :10.1192/
bjp.bp.112.120808.
Lee, S. S., Humphreys, K. L., Flory, K., Liu, R., & Gl ss, K. (2011). 
Prospective association of childhood attention-deficit/hyperactiv-
ity disorder (ADHD) and substance use and abuse/dependence: 
J Autism Dev Disord (2017) 47:80–8988
123
of General Psychiatry, 69(11), 1099–1103. doi:10.1001/
archgenpsychiatry.2012.730.
Sundquist, J., Sundquist, K., & Ji, J. (2014) Autism and attention-
deficit/hyperactivity disorder among individuals with a family 
history of alcohol use disorders. Elife, 3:e02917. doi:10.7554/
eLife.02917
Wettermark, B., Hammar, N., Fored, C. M., Leimanis, A., Otterblad 
Olausson, P., Bergman, U., et al. (2007). The new Swedish pre-
scribed drug register–opportunities for pharmacoepidemiological 
research and experience from the first six months. Pharmaco-
epidemiology and Drug Safety, 16(7), 726–735. doi:10.1002/
pds.1294.
WHO. (2014). Global status report on alcohol and health 2014. 
Geneva: World Health Organization.
Zuo, L., Wang, K., Zhang, X. Y., Pan, X., Wang, G., Tan, Y., et al. 
(2013). Association between common alcohol dehydrogenase 
gene (ADH) variants and schizophrenia and autism. Human 
Genetics, 132(7), 735–743. doi:10.1007/s00439-013-1277-4.
Skoglund, C., Chen, Q., Franck, J., Lichtenstein, P., & Larsson, H
(2014). Attention-deficit/hyperactivity disorder and risk for 
substance use disorders in relatives.Biological Psych atry.
doi:10.1016/j.biopsych.2014.10.006.
Statistics Sweden. (1992). Population and housing census 1990. Part 
6, income and education. Stockholm: Statistics Sweden.
Statistics Sweden. (2011a). Education l attainmen  of the population
2010. Stockholm: Statistics Sweden.
Statistics Sweden. (2011b). Labour and education statistics. Inte-
grated database for labour market res a ch. Stockholm: Statis-
tics Sweden.
Stevens, S. A., Nash, K., Koren, G., & Rovet, J  (2013). Autism char-
acteristics in children with fetal alc ho spectrum disorders. Child 
Neuropsychology, 19(6), 579–587. doi:0.1080/09297049.2012.
727791.
Sullivan, P. F., Magnusson, C., Reichenberg, A., Boman, M., Dal-
man, C., Davidson, M., et al. (2012). Family history of schizo-
phrenia and bipolar disorder as risk factors f r autism. A chives 
J Autism Dev Disord (2017) 47:80–89 89
123
